Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.
The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.
Rallybio Corp. (RLYB) anticipates that its merger with Avenzo Therapeutics will close after trading on November 20, 2026, subject to satisfaction or waiver of outstanding closing conditions; Nasdaq approved listing Rallybio common stock on the Nasdaq Capital Market in connection with the merger. The previously announced $13.90-per-share cash distribution remains payable to stockholders and pre-funded warrant holders of record November 5, with entitlements affected by trades during Nasdaq’s due bill period.
The due bill period runs from November 5 through the close of trading on November 20: buyers during that period are entitled to the distribution and sellers are not, even if trades settle later. The transfer agent is expected to begin payments November 30, after the distribution amount is deposited November 19. Contingent value rights are expected to be distributed November 23. The reverse stock split is expected to take effect at 4:01 p.m. Eastern Time on November 20, without changing the distribution’s timing or amount.
Rallybio Corp. (RLYB) anticipates that its merger transactions with Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc. will close after trading on November 20, 2026, subject to satisfaction or waiver of outstanding closing conditions. Nasdaq approved listing Rallybio common stock on the Nasdaq Capital Market in connection with the merger.
Rallybio’s special cash distribution is $13.90 per share, payable to stockholders and pre-funded warrant holders based on their holdings as of the November 5, 2026 record date and during the due-bill period. The period runs through the close of trading on November 20; buyers during it are entitled to the distribution and sellers are not, even if trades settle later. The transfer agent is expected to begin payments on November 30, with holders expected to receive them within a few days. The distribution is expected to be deposited with the transfer agent on November 19.
The expected ex-dividend date is November 23, 2026. Rallybio’s reverse stock split is expected to take effect at 4:01 p.m. Eastern Time on November 20 and will not change the distribution’s timing or amount. Contingent value rights are expected to be distributed on November 23 to holders of record as of the record date of common stock, pre-funded warrants, restricted stock units and In the Money Parent Options.
Rallybio Corporation (RLYB) announced a one-for-two reverse stock split of its issued and outstanding common stock, expected to take effect at 12:01 a.m. Eastern Time on November 20, 2026, before the anticipated merger with Avenzo Therapeutics.
The split is expected to reduce issued and outstanding shares from approximately 5.6 million to approximately 2.8 million before giving effect to the merger closing. Each two shares will be combined into one; the authorized number of common shares and the $0.0001 par value per share will remain unchanged. Stockholders entitled to fractional shares will instead receive cash based on the fractional shares’ fair market value, using the closing stock price on the effective date. Proportionate adjustments will be made to outstanding pre-funded warrants, equity awards and equity plan reserves under their applicable terms.
Following applicable Nasdaq approvals and merger closing, Rallybio plans to change its name to Avenzo Therapeutics, Inc.
Rallybio Corporation (RLYB) approved a one-for-two reverse stock split, expected to take effect at 12:01 a.m. Eastern Time on November 20, 2026.
Before the merger, issued and outstanding common shares are expected to decrease from approximately 5.6 million to approximately 2.8 million. The split will not change the authorized share count or the $0.0001 par value per share; shares underlying pre-funded warrants and equity awards, and equity plan reserves, will be adjusted proportionately under their applicable terms. Holders otherwise entitled to fractional shares will receive cash based on the fair market value of the fraction, using the closing price on the effective date. After applicable Nasdaq approvals and merger closing, Rallybio plans to change its name to Avenzo Therapeutics, Inc. and trade under the symbol AVZO.
Rallybio Corp (RLYB) and Avenzo Therapeutics, Inc. postponed the closing of their merger, which Rallybio had anticipated for November 6, 2026, subject to outstanding closing conditions. The parties said certain conditions related to listing Rallybio shares following the closing were not satisfied and that they would continue seeking the applicable listing approvals. Farmington Merger Sub, Inc. is also a party to the merger agreement.
Because the closing was postponed, Rallybio did not deposit funds for the previously announced cash distribution with Computershare on November 5, 2026. The distribution’s previously announced payment date and ex-dividend date may be delayed. Rallybio said it would provide further updates as it deems appropriate or necessary under applicable law and regulations.
Rallybio Corp director Martin Mackay exercised three stock options on November 4, 2026, acquiring 33,224 Common Stock shares in total. The exercises covered 11,607 shares at $7.60 per share, 3,562 at $2.38 and 18,055 at $4.45. The options expire January 2, 2035, May 13, 2035 and February 18, 2036, respectively. Two options were issued in lieu of retainer fees of $65,000 each.
Rallybio Corp director Ronald Hunt exercised options for 14,305 shares of common stock on November 4, 2026, at an exercise price of $4.45 per share. He directly held 29,125 shares of common stock after the transaction. The option was issued under the company's 2021 Equity Incentive Plan in lieu of $51,500 in retainer fees; its vesting was accelerated in full, and it became fully vested and exercisable on October 26, 2026.
Rallybio Corp. stockholders approved the merger-related issuance of common stock to Avenzo securityholders, which will represent more than 20% of shares outstanding immediately before the merger and result in a change of control. The merger is expected to close November 6, 2026, subject to satisfaction or waiver of outstanding closing conditions.
Stockholders also approved a reverse split ranging from 1-for-2 to 1-for-9, with the final ratio to be mutually determined by Rallybio and Avenzo; neither intends to effect it before merger closing. They approved changing the company name to Avenzo Therapeutics, Inc. and increasing authorized common stock from 200,000,000 to 500,000,000 shares. The 2026 equity plan’s initial reserve is 18% of post-merger common stock issued and outstanding; the employee stock purchase plan’s initial limit is 1% of shares issued and expected to be outstanding immediately after the merger. Both plans are contingent on closing.
Rallybio set an aggregate $83.6 million cash distribution, or $13.90 per share, for stockholders and pre-funded warrant holders of record November 5, 2026, subject to due-bill procedures. The due-bill period runs through the close of trading November 6, and the transfer agent is expected to begin payments November 13.
Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options for 7,124 common shares on November 2, 2026, at an exercise price of $14.88 per share. After the exercise, he directly held 44,139 common shares, and the reported option position was zero. The options were granted under Rallybio's 2021 Equity Incentive Plan.